Vidac Pharma's Promising Pediatric Cancer Data

Vidac Pharma Holding Plc received a "Buy" recommendation from Sphene Capital GmbH, which set a target price of EUR 4.30 per share. Despite a lower target compared to a previous estimate of EUR 4.90, the outlook remains positive. Vidac's value is assessed through a detailed multi-stage discounted cash flow model, reflecting expected future earnings and risks.

Recent trials highlighted promising pharmacokinetic results for Almavid in pediatric brain cancer patients. Almavid, with active ingredient VDA 1102, interferes with cancer cell enzymes, potentially offering new treatment avenues. The study showed sustained stability and strong dose linearity in three children, showcasing its potential as a broad-spectrum therapeutic agent.